Forum Topic News
  • Conversation: FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)

    • December 14, 2018 12:44 PM GMT
    • FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)

      Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE). The Fast Track designation process aims to facilitate the development and expedite the review of new medicines that treat serious conditions and fill unmet medical needs, with the goal of delivering potentially important therapies to patients sooner.
      Read more: https://prn.to/2PBvKt5

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč